24/7
Buzz
Startups
VC
AI
Innovation
Opinions
Events
Promising Startups 2024
BiblioTech
Boarding Pass
Corporate
Appointments
CTalk
Tech Gateways
2025 VC survey
@Finance
Ctech Testimonials
Shopping
Projects
About
Newsletter
Contact us
RSS
Facebook
Twitter
ACCESSIBILITY
by
Homepage
Compugen
Tags search
HOME
24/7
buzz
STARTUPS
VC
AI
Innovation
OPINIONS
EVENTS
SHOPPING
ABOUT
Terms Of Use
Privacy Policy
NEWSLETTER
SEARCH
CONTACT US
ACCESSIBILITY
24/7
Headlines
20:41
OpenAI acquires Jony Ive’s startup in $6.5 billion push into AI hardware
14:18
"Every market downturn is a chance to focus, cut unnecessary spending, and double down on what you do best"
14:01
Pango backs out of $175 million merger with Gett
13:18
CyFox CEO Yossi Tal: “There is no other agentic compliance solution in the market like ours”
More stories
Buzz
Most popular
Daily
Weekly
1
Intel considering selling off networking business in strategic overhaul
2
“Execution, execution, execution”: Intel CEO vows to rebuild through results
3
Gigi Levy-Weiss and Redis co-founder Yiftach Shoolman launch defense tech startup Line 5, raising $20M Seed round
4
The 50 most promising Israeli startups - 2025
5
Cyber startup Cyera raising hundreds of millions at over $6 billion valuation
More news
Compugen
5 stories about Compugen
Compugen shares soar on massive deal with Gilead, worth up to $848 million
19.12.23
|
Sophie Shulman
The Israeli company utilizes its broadly applicable predictive computational discovery capabilities to identify new drug targets and biological pathways for developing novel cancer immunotherapies
Compugen Falls 17% on Employee Cuts Announcement
27.02.19
|
Lilach Baumer
The Nasdaq-listed cancer immunotherapy company published its fourth quarter and full year results for 2018 Tuesday
Bristol-Myers Squibb Invests $12 Million in Israeli Immunotherapy Company Compugen
12.10.18
|
Dror Reich
The investment is part of a clinical trial collaboration for a treatment that combines Compugen’s investigational antibody with an immune checkpoint inhibitor from Bristol-Myers Squibb
Biotech Company Compugen Down on Nasdaq Following $21 Million Direct Offering
17.06.18
|
Dror Reich
The Israel-based cancer immunotherapy company intends to use the proceedings for product development
AstraZeneca Signs Deal with Cancer Immunotherapy Company Compugen
03.04.18
|
Lilach Baumer
The deal has the potential to be worth over $200 million for Nasdaq-listed Compugen